I have not been what you would call a supporter of healthcare giant Johnson & Johnson (JNJ) in my articles on Seeking Alpha, my old article on why I sold the shares having generated quite a bit of controversy. Companies and stocks are not static entities, though, and every responsible investor owes it to themselves to revisit stories and theses from time to time.
In With The New
Quite a lot has changed at J&J over the past year. Although the device market is still pretty sluggish, the company has been active in shuffling its deck. The company decided to throw in the towel and cede the drug-coated stent market to the likes of Abbott Labs (ABT), Boston Scientific (BSX), and Medtronic (MDT), while significantly strengthening its orthopedics business with the acquisition of Synthes. Once this deal closes (probably in the first half of 2012), JNJ will be a much bigger player in spine and trauma.
Read more here:
Reconsidering The Case For Johnson & Johnson
No comments:
Post a Comment